The subtype-selective nicotinic acetylcholine receptor positive allosteric potentiator 2087101 differentially facilitates neurotransmission in the brain

• Published in: European journal of pharmacology Vol. 643; no. 2; pp. 218 - 224
• Main Authors: de Filippi, Giovanna, Mogg, Adrian J., Phillips, Keith G., Zwart, Ruud, Sher, Emanuele, Chen, Ying
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier B.V 25.09.2010; Elsevier
• Subjects: Allosteric Regulation; alpha7 Nicotinic Acetylcholine Receptor; Animals; Animals, Newborn; Biological and medical sciences; Cells, Cultured; Dopamine neuron firing; Excitatory Postsynaptic Potentials - drug effects; GABA; Hippocampus; Hippocampus - cytology; Hippocampus - drug effects; Hippocampus - metabolism; Male; Medical sciences; Neurons - drug effects; Neurons - metabolism; Nicotinic acetylcholine receptors; Nicotinic Agonists - pharmacology; Noradrenaline release; Norepinephrine - metabolism; Osmolar Concentration; Pharmacology. Drug treatments; Positive allosteric modulator; Protein Isoforms - metabolism; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Nicotinic - metabolism; Synaptic Transmission - drug effects; Thiazoles - pharmacology; Time Factors; Ventral tegmental area; Ventral Tegmental Area - drug effects; Ventral Tegmental Area - metabolism; Noradrenaline release; Nicotinic acetylcholine receptors; GABA; Positive allosteric modulator; Ventral tegmental area; Dopamine neuron firing; Hippocampus; Central nervous system; Catecholamine; Encephalon; Cholinergic receptor; Allosteric regulation; Neurotransmitter; Dopaminergic neuron; Norepinephrine; Nicotinic receptor; Release; Neurotransmission
• ISSN: 0014-2999; 1879-0712; 1879-0712
• DOI: 10.1016/j.ejphar.2010.06.064

Positive allosteric modulators of centrally expressed nicotinic acetylcholine receptors have therapeutic potentials in areas of cognition, motor function and reward. Several chemical classes of allosteric modulators that are selective for α7 nicotinic receptors have been characterised, but potentiators for the most widely expressed α4β2 nicotinic receptor subtype are few and less defined, owing probably to the difficulty to achieve selectivity over other heteromeric receptor subtypes. 2087101 (2-amino-5-keto)thiazole) is a potent potentiator of both α7 and α4β2 receptors and it has selectivity against the α3β4 subtype, which may be responsible for the undesirable peripheral side effects. To further characterise its ability to differentiate between native nicotinic receptors, we examined the effects of 2087101 on α7, α4β2* and α3β4* receptor-mediated responses in the rat brain in electrophysiological and neurochemical experiments. 2087101 significantly potentiated agonist-induced, α7 and non-α7 receptor-mediated, GABAergic postsynaptic currents in cultured hippocampal neurones, but not the nicotine-stimulated [ 3H]noradrenaline release from hippocampal slices, which was primarily mediated by α3β4* receptors, confirming its selectivity for α7 and α4β2* receptors in native systems. 2087101 also significantly enhanced nicotine-stimulated firing increase in dopamine neurones of the ventral tegmental area, an effect that was dihydro-β-erythroidine-sensitive and thereby mediated by α4β2* nicotinic receptors. 2087101 can therefore enhance native nicotinic activities mediated by α7 and α4β2*, but not α3β4* receptors, showing its unique ability to discriminate between native heteromeric nicotinic receptor subtypes and its therapeutic potential for treating brain disorders by concurrent modulation of both α7 and α4β2* nicotinic receptors.